An acute and long-term study with a dispersible formulation of levodopa/benserazide (Madopar®) in Parkinson's disease

A. Monge, L. Barbato, G. Nordera, F. Stocchi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The clinical efficacy, tolerability and administration regimens of a dispersible formulation of levodopa/benserazide (DM) were investigated in 30 patients with idiopathic Parkinson's disease, complicated by motor fluctuations. All 30 patients showed delayed-'on' phenomenon after administration of the first morning dose of standard levodopa (SM), and 20 showed delayed-'on' phenomenon after the first afternoon dose. Patients were receiving standard formulations of levodopa as monotherapy or in combination. A double-dose study of the dispersible vs the standard formulation was performed in 30 patients, 24 of whom participated in a 36-month, follow-up clinical study. In the long-term study, SM was replaced with DM by substituting the first morning dose or the first morning and first afternoon doses. In the double-dose study, mean latency to 'on' after the first morning dose was significantly shorter with DM than with SM (p <0.001), whereas the duration of 'on' was similar with the two preparations. The post-prandial delayed-'on' in the 14 patients who responded to therapy was significantly shorter for DM than for SM (p <0.001). In the long-term study, the mean latency to 'on' in all patients was significantly shorter than at baseline (p <0.001). Time spent in 'on' during the active day increased significantly, and remained stable during the 36-month study. No changes were apparent in the mean dosage of levodopa/day or the number of doses/day, and no acute or long-term adverse events were reported. In conclusion, these results confirm the long-term safety of the dispersible formulation, and its improved efficacy compared with standard levodopa formulations, as monotherapy and in association with slow-release formulations.

Original languageEnglish
Pages (from-to)485-490
Number of pages6
JournalEuropean Journal of Neurology
Volume4
Issue number5
Publication statusPublished - 1997

Fingerprint

Parkinson Disease
Levodopa
Meals
levodopa drug combination benserazide
Safety

Keywords

  • Levodopa/benserazide
  • Motor fluctuations
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

An acute and long-term study with a dispersible formulation of levodopa/benserazide (Madopar®) in Parkinson's disease. / Monge, A.; Barbato, L.; Nordera, G.; Stocchi, F.

In: European Journal of Neurology, Vol. 4, No. 5, 1997, p. 485-490.

Research output: Contribution to journalArticle

@article{b3f3cfe804004d58a90233f8c5bf6fe8,
title = "An acute and long-term study with a dispersible formulation of levodopa/benserazide (Madopar{\circledR}) in Parkinson's disease",
abstract = "The clinical efficacy, tolerability and administration regimens of a dispersible formulation of levodopa/benserazide (DM) were investigated in 30 patients with idiopathic Parkinson's disease, complicated by motor fluctuations. All 30 patients showed delayed-'on' phenomenon after administration of the first morning dose of standard levodopa (SM), and 20 showed delayed-'on' phenomenon after the first afternoon dose. Patients were receiving standard formulations of levodopa as monotherapy or in combination. A double-dose study of the dispersible vs the standard formulation was performed in 30 patients, 24 of whom participated in a 36-month, follow-up clinical study. In the long-term study, SM was replaced with DM by substituting the first morning dose or the first morning and first afternoon doses. In the double-dose study, mean latency to 'on' after the first morning dose was significantly shorter with DM than with SM (p <0.001), whereas the duration of 'on' was similar with the two preparations. The post-prandial delayed-'on' in the 14 patients who responded to therapy was significantly shorter for DM than for SM (p <0.001). In the long-term study, the mean latency to 'on' in all patients was significantly shorter than at baseline (p <0.001). Time spent in 'on' during the active day increased significantly, and remained stable during the 36-month study. No changes were apparent in the mean dosage of levodopa/day or the number of doses/day, and no acute or long-term adverse events were reported. In conclusion, these results confirm the long-term safety of the dispersible formulation, and its improved efficacy compared with standard levodopa formulations, as monotherapy and in association with slow-release formulations.",
keywords = "Levodopa/benserazide, Motor fluctuations, Parkinson's disease",
author = "A. Monge and L. Barbato and G. Nordera and F. Stocchi",
year = "1997",
language = "English",
volume = "4",
pages = "485--490",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - An acute and long-term study with a dispersible formulation of levodopa/benserazide (Madopar®) in Parkinson's disease

AU - Monge, A.

AU - Barbato, L.

AU - Nordera, G.

AU - Stocchi, F.

PY - 1997

Y1 - 1997

N2 - The clinical efficacy, tolerability and administration regimens of a dispersible formulation of levodopa/benserazide (DM) were investigated in 30 patients with idiopathic Parkinson's disease, complicated by motor fluctuations. All 30 patients showed delayed-'on' phenomenon after administration of the first morning dose of standard levodopa (SM), and 20 showed delayed-'on' phenomenon after the first afternoon dose. Patients were receiving standard formulations of levodopa as monotherapy or in combination. A double-dose study of the dispersible vs the standard formulation was performed in 30 patients, 24 of whom participated in a 36-month, follow-up clinical study. In the long-term study, SM was replaced with DM by substituting the first morning dose or the first morning and first afternoon doses. In the double-dose study, mean latency to 'on' after the first morning dose was significantly shorter with DM than with SM (p <0.001), whereas the duration of 'on' was similar with the two preparations. The post-prandial delayed-'on' in the 14 patients who responded to therapy was significantly shorter for DM than for SM (p <0.001). In the long-term study, the mean latency to 'on' in all patients was significantly shorter than at baseline (p <0.001). Time spent in 'on' during the active day increased significantly, and remained stable during the 36-month study. No changes were apparent in the mean dosage of levodopa/day or the number of doses/day, and no acute or long-term adverse events were reported. In conclusion, these results confirm the long-term safety of the dispersible formulation, and its improved efficacy compared with standard levodopa formulations, as monotherapy and in association with slow-release formulations.

AB - The clinical efficacy, tolerability and administration regimens of a dispersible formulation of levodopa/benserazide (DM) were investigated in 30 patients with idiopathic Parkinson's disease, complicated by motor fluctuations. All 30 patients showed delayed-'on' phenomenon after administration of the first morning dose of standard levodopa (SM), and 20 showed delayed-'on' phenomenon after the first afternoon dose. Patients were receiving standard formulations of levodopa as monotherapy or in combination. A double-dose study of the dispersible vs the standard formulation was performed in 30 patients, 24 of whom participated in a 36-month, follow-up clinical study. In the long-term study, SM was replaced with DM by substituting the first morning dose or the first morning and first afternoon doses. In the double-dose study, mean latency to 'on' after the first morning dose was significantly shorter with DM than with SM (p <0.001), whereas the duration of 'on' was similar with the two preparations. The post-prandial delayed-'on' in the 14 patients who responded to therapy was significantly shorter for DM than for SM (p <0.001). In the long-term study, the mean latency to 'on' in all patients was significantly shorter than at baseline (p <0.001). Time spent in 'on' during the active day increased significantly, and remained stable during the 36-month study. No changes were apparent in the mean dosage of levodopa/day or the number of doses/day, and no acute or long-term adverse events were reported. In conclusion, these results confirm the long-term safety of the dispersible formulation, and its improved efficacy compared with standard levodopa formulations, as monotherapy and in association with slow-release formulations.

KW - Levodopa/benserazide

KW - Motor fluctuations

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0030776188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030776188&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030776188

VL - 4

SP - 485

EP - 490

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 5

ER -